Regn Stock Forecast Zacks

This quarterly report represents an earnings surprise of 56.68%. Seven analysts have provided estimates for regeneron pharmaceuticals'.

Is Regeneron Pharmaceuticals Regn A Worthy Stock Now

The zacks rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that regn has an improving earnings outlook.

Regn stock forecast zacks. Regn is currently sporting an improving earnings outlook, which makes it stick out in our zacks rank model. Equities analysts forecast that regeneron pharmaceuticals, inc. Regn currently has a forward p/e ratio of 11.67, while incy has a forward p/e of 26.98.

And, based on the above valuation metrics, we feel that regn is likely the superior. Regn is currently sporting an improving earnings outlook, which makes it stick out in our zacks rank model. See the report's 7 new picks today.

We also note that regn has a peg ratio of 0.64. The zacks rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that regn has an improving earnings outlook. The price has risen in 6 of the last 10 days and is up by 3.35% over the past 2 weeks.

(nasdaq:regn) will announce sales of $4.39 billion for the current fiscal quarter, zacks investment research reports. And, based on the above valuation metrics, we feel that regn is likely the superior. The zacks rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that regn has.

Each stock is a zacks rank #1 strong buy. Since then, regn shares have increased by 36.7% and is now trading at $635.16. This compares to earnings of $8.36 per share a year ago.

Regn gets ec nod for cocktail, biib's drug approval & more nov. Symbol last price market cap % δ 1 yr % δ 5 yr; This change lagged the s&p 500's daily gain of 0.23%.

17, 2021 at 10:29 a.m. Regeneron pharmaceuticals $630.59 $66b 23.4% 69.5% ilmn. Prior to today's trading, shares of the biopharmaceutical.

For the regeneron pharmaceuticals, inc. And, based on the above valuation metrics, we feel that regn is likely the superior. Get the latest regeneron pharmaceuticals, inc.

Regn investment & stock information. Stocks with a grades for value and high zacks ranks are among the best value stocks available at any given moment. Regn is currently sporting an improving earnings outlook, which makes it stick out in our zacks rank model.

Compare regn stock to peers. Regn is currently sporting a zacks rank of #1 (strong buy). A quarter ago, it was expected that this.

Regeneron (regn) came out with quarterly earnings of $15.37 per share, beating the zacks consensus estimate of $9.81 per share. Et on zacks.com pfizer (pfe) seeks fda's emergency use nod for covid pill Forecast (traded under symbol regn) for one year forward price target at the top of this page, we have presented the average regn forecast for forward target price across the 15 analysts covering regn, as reported in data provided by.

Given that regn has a zacks rank #1 (strong buy) and an esp in positive territory, investors might want to consider this stock ahead of earnings. During the day the stock fluctuated 3.03% from a day low at $640.88 to a day high of $660.28. One stock to keep an eye on.

3 Reasons To Invest In Regeneron Pharmaceuticals Regn Now Nasdaq